IMPACT OF DIABETES MELLITUS ON STEMI PRESENTATION AND CORONARY VESSEL DISEASE IN PATIENTS UNDERGOING PCI: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.71000/qbshbz07Keywords:
ST-segment elevation myocardial infarction (STEMI), , Diabetes mellitus (DM), , Coronary artery disease (CAD), , Percutaneous coronary intervention (PCI) , Risk Factors, Troponin, Vascular DiseasesAbstract
Background: ST-segment elevation myocardial infarction (STEMI) remains one of the most critical manifestations of coronary artery disease, contributing significantly to global morbidity and mortality. Diabetes mellitus (DM) is recognized as an independent risk factor for adverse cardiovascular outcomes and is often associated with more complex coronary artery involvement. However, the specific relationship between diabetes and the angiographic patterns of STEMI in South Asian populations undergoing percutaneous coronary intervention (PCI) remains insufficiently characterized.
Objective: This study aimed to compare the extent of coronary vessel disease and the type of STEMI presentation between diabetic and non-diabetic patients undergoing PCI, while also describing their demographic, clinical, and procedural characteristics.
Methods: A cross-sectional observational study was conducted at the Peshawar Institute of Cardiology from January to June 2025. A total of 150 patients with STEMI who underwent PCI were enrolled. Inclusion criteria required age ≥18 years, confirmation of STEMI through clinical presentation, electrocardiographic changes, and elevated cardiac biomarkers. Patients with prior CABG, advanced malignancy, or end-stage renal failure were excluded. Data collected included demographics, comorbidities, initial troponin levels, angiographic findings, and procedural characteristics. Patients were stratified by diabetes status. Descriptive statistics and chi-square tests were applied, with significance set at p < 0.05.
Results: The mean age of patients was 58.03 ± 10.74 years (range 34–79), with 71.3% males and 28.7% females. Hypertension (68%) and diabetes (28%) were the most frequent comorbidities, followed by tobacco use (14%). Initial troponin values ranged from 2.0 to 50,000 ng/mL (mean 12,111.50 ± 18,556.98). Coronary angiography revealed single-vessel disease in 44.0%, double-vessel disease in 36.7%, and triple-vessel disease in 19.3%. Among diabetic patients (n = 42), single-vessel disease was present in 42.9%, double-vessel in 35.7%, and triple-vessel in 21.4%. In the same group, 47.6% underwent PCI for primary indication, while anterior, lateral, and inferior wall STEMI presentations were seen in 19.0%, 23.8%, and 9.5% respectively. Statistical analysis demonstrated no significant association between diabetes and vessel involvement (p = 0.921) or type of STEMI presentation (p = 0.804).
Conclusion: Diabetes mellitus was not significantly associated with the angiographic extent of coronary disease or the clinical presentation of STEMI in this cohort. These findings underscore the importance of comprehensive risk factor management in all STEMI patients undergoing PCI, regardless of diabetic status.
References
Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord [Internet]. 2023;23(1):206.
Ansari S, Imran M, Kumar Gupta P. Journal of Population Therapeutics and Clinical Pharmacology. J Popul Theapeutics Clin Pharmacol. 2024;31(6):170–5.
Thrane PG, Olesen KKW, Thim T, Gyldenkerne C, Mortensen MB, Kristensen SD, et al. Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2023;82(10):999–1010.
Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. Rev Cardiovasc Med. 2024;25(12).
Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Heal Sci reports. 2024 Mar;7(3):e2004.
Jamshaid Taj. Diabetes Mellitus – The Epidemic of 21 Century. Esculapio [Internet]. 2023;19(1):1–2.
Scudeler TL, Alves da Costa LM, de Oliveira Silva Filho JR, Belo Nunes RA, Schneidewind RO, Brito TM, et al. Revascularization in Diabetic Patients with Non-ST-Elevation Acute Myocardial Infarction. Mayo Clin proceedings Innov Qual outcomes. 2025 Jun;9(3):100604.
Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. Rev Cardiovasc Med. 2024 Dec;25(12):436.
Heusch G. Myocardial ischemia/reperfusion: Translational pathophysiology of ischemic heart disease. Med [Internet]. 2024;5(1):10–31.
Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, et al. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines. 2022 Sep;10(9).
Heusch G. Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol. 2022 Jan;117(1):1.
Akhrass R, Bakaeen FG. The advantage of surgical revascularization in diabetic patients with multivessel disease: More arterial conduits, more benefit. J Thorac Cardiovascular Surgical [Internet]. 2022;164(1):119–22.
Aslanabadi N, Mashayekhi S, Rezvani M, Abdollahzadeh A, Hajialigol A. A Comparison Between Culprit Versus Complete Revascularization in Diabetic Patients With Acute Myocardial Infarction. Clin Cardiol. 2024 Nov;47(11):e70046.doi: 10.1002/clc.70046
Yang Y, Hyun J, Lee J, Kim JH, Lee JB, Kang DY, et al. Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus. JACC Asia. 2021 Sep;1(2):173–84.
Soleimani H, Karimi E, Mahalleh M, Entezari FJ, Nasrollahizadeh A, Nasrollahizadeh A, et al. Abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2025 Apr;25(1):343.
Fluder-Wlodarczyk J, Pawłowski S, Chuchra PJ, Pawłowski T, Wojakowski W, Gasior P. Importance of Short-Term Neointimal Coverage of Drug-Eluting Stents in the Duration of Dual Antiplatelet Therapy. J Clin Med. 2024;13(6).
Eigbire-Molen O, Hermelin D, Blackall D. Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis. J Med Cases [Internet]. 2022;13(6):274–80.
Aggarwal R, Yeh RW, Joynt Maddox KE, Wadhera RK. Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020. JAMA. 2023 Mar;329(11):899–909.
Qamar A, Bhatia K, Arora S, Hendrickson M, Gupta P, Fatima A, et al. Clinical Profiles, Outcomes, and Sex Differences of Patients With STEMI: Findings From the NORIN-STEMI Registry. JACC Asia [Internet]. 2023;3(3):431–42.
Tarabih M, Ovdat T, Karkabi B, Barel MS, Muhamad M, Beigel R, et al. Characteristics, management and outcome of patients with late-arrival STEMI in the Acute Coronary Syndrome Israeli Surveys (ACSIS). Int J Cardiol Hear Vasc. 2024 Aug; 53:101476.
Omer MA, Brilakis ES, Kennedy KF, Alkhouli M, Elgendy IY, Chan PS, et al. Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. JACC Cardiovasc Interv. 2021;14(10):1067–78.
Michael Megaly, Christian W. Schmidt, Marshall W. Dworak, Ross Garberich, Larissa Stanberry, Scott Sharkey, Emmanouil S. Brilakis, Frank V. Aguirre, Roberto Pacheco, Mark Tannenbaum, Teresa Coulson, Timothy D. Smith, Timothy D. Henry SG. Diabetic Patients Who Present With ST-Elevation Myocardial Infarction, 2022. p. 89-93.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Safa Gul, Shifa Shakir, Seraj Ud Din, Hazrat Usman, Babar Ali (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
